The presentations will include new findings on mogamulizumab’s therapeutic benefit, safety, and pharmacodynamic profile, and insight into alternative dosing strategies, real-world treatment patterns, ...
Kyowa Kirin’s big bet on Kura Oncology has paid off in short order, delivering an FDA approval for a medicine to treat a ...
Pharmaceutical Technology on MSN
Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy
Komzifti now becomes the first once-daily targeted therapy for r/r AML, though it will have to fight Syndax’s Revuforj for ...
Japan's Kirin Holdings is seeking to exit its investment in Bira 91. The company holds a significant stake in the Indian ...
NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients –– Acute unmet need in R/R ...
Kirin Holdings' Institute for Future Beverage recently developed a fermented ingredient from coffee cherries to promote sustainability in coffee farming and enhance non-alcoholic and low-alcohol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback